My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 775 / https://doi.org/10.3332/ecancer.2017.775

Clinical Study

Laparoscopic liver resection in metastatic colorectal cancer treatment: comparison with long-term results using the conventional approach

Background: Laparoscopic liver resections (LLRs) have been shown to be both feasible and safe. However, no randomised control studies have been performed to date comparing results with those of the open surgery approach.

Main aim: To analyse LLR long-term results and compare them with a similar group of open resections in patients with colorectal carcinoma liver metastasis (CRCLM).

Methods: Retrospective study on a prospective database. All patients with anatomopathological diagnosis of CRCLM resected between July 2007 and July 2015.

Results: Twenty-two open resections and 18 laparoscopic resections which presented favourable lesions for laparoscopic approach were analysed. Postoperative grade III morbidity was similar in both groups (p = 0.323). Disease-free survival at 1, 3, and 8 years in the laparoscopy group (n =16) was 81%, 58%, and 58%, respectively, while in the open surgery group (n = 17) it was 64%, 37%, and 19% respectively; no differences were found (p = 0.388). Global survival in the laparoscopy group was 93%, 60%, and 40%, respectively, and 88%, 74.5%, and 58.7%, respectively, in the open surgery group; no differences were found (p = 0.893) with a 37 months average follow-up.

Conclusion: LLR in patients with technically favourable CRCLM had similar morbidity to open resections and resection margins were not compromised because of laparoscopy.

Keywords: Laparoscopic liver surgery, liver surgery, colorectal cancer, liver metastases

Loading Article Metrics ... Please wait

Related articles

Short Communication: Cancer treatment in the last 6 months of life: when inaction can outperform action

Abstract | Full Article | PDF Published: 18 Apr 2018 / https://doi.org/10.3332/ecancer.2018.826

Research: Evidence on the cost of breast cancer drugs is required for rational decision making

Abstract | Full Article | PDF Published: 16 Apr 2018 / https://doi.org/10.3332/ecancer.2018.825

Clinical Study: Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents

Abstract | Full Article | PDF Published: 11 Apr 2018 / https://doi.org/10.3332/ecancer.2018.824

Review: Risk sharing agreements, present and future

Abstract | Full Article | PDF | Portuguese Published: 10 Apr 2018 / https://doi.org/10.3332/ecancer.2018.823

Conference Report: Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt

Abstract | Full Article | PDF Published: 22 Mar 2018 / https://doi.org/10.3332/ecancer.2018.820



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence